Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

4 Stocks On The Move: EYES, FEYE, TGTX, ZIOP

Published 02/26/2015, 02:24 AM
Updated 07/09/2023, 06:31 AM

It was an interesting day yesterday on Wall Street, up nicely in the morning to new all-time highs, and then rolled them over, and rolled them over hard before a late bounce. Perhaps it’s a sign that the market wants to take a rest, but we’ll just have to wait and see what happens in the next few days.

Second Sight Medical Products, (NASDAQ:EYES) has had two consecutive big days with big volume. It broke through resistance on Wednesday, up 2.70 to 13.90, or 24%, on 9.8 million shares. The next target on EYES if it gets a follow-through is 16-16 1/4-1/2. But at some point shortly it’s going to get some pullback consolidation.

FireEye, (NASDAQ:FEYE) was up 1.43 to 45.40, or 31/4%, on 15.7 million shares. This stock has had some very nice action after the run-up and break out of the base. The pullback has held some four or five days now above the 42 1/2 range. If it can get above the recent spike high at 46.18, it could see 50-51, which is the next target.

TG Therapeutics, (NASDAQ:TGTX) popped 1.51 to 15.26 or 11%, on 1.25 million shares on Wednesday. That’s the best volume in two months. The next target on this one should it extend will be up to 15 1/2, and the double-top at 18.

ZIOPHARM Oncology, (NASDAQ:ZIOP) had a run-up late in the day on Wednesday, up 60 cents to right near the high for the day at 10.50, or 6%, on 3.3 million shares. This looks like an accelerating, rising flag that could explode toward 14 1/2-15 short-term target.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Other stocks on Harry’s Charts of the Day included Advaxis, (NASDAQ:ADXS), Biocept, (NASDAQ:BIOC), BroadSoft, (NASDAQ:BSFT), EPIRUS Biopharmaceuticals, (NASDAQ:EPRS), First Solar, (NASDAQ:FSLR), Helios and Matheson Analytics (HMNY), Nuverra Environmental Solutions, (NYSE:NES), Opko Health, (OPK), Regulus Therapeutics (NASDAQ:RGLS), the Rubicon Project, (NYSE:RUBI), and Sorrento Therapeutics, (NASDAQ:SRNE)).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.